324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

Our colleague Jonathan Wosen joins us to discuss the recent setbacks and wins in oncology R&D, including Genentech's decision to shut down its cancer immunology group, and the global ambitions of Akeso, the Chinese biotech behind Summit Therapeutics’ recent positive results. We also chat about the latest news in the life sciences, including Pfizer’s sudden announcement to pull its sickle cell drug and the imminent approval of Bristol Myers Squibb’s schizophrenia treatment.

Episode metadata supplied by the publisher feed · Published Sep 26, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

324: Genentech's cancer pivot, Pfizer's sickle cell withdrawal, and a new schizophrenia drug

0:00 32:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Readout Loud?

This episode is 32 minutes long.

When was this The Readout Loud episode published?

This episode was published on September 26, 2024.

Can I download this The Readout Loud episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!